- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03595631
Neurodynamic Interventions for Multiple Sclerosis
October 19, 2018 updated by: César Fernández-de-las-Peñas, Universidad Rey Juan Carlos
Effects of Neurodynamic Interventions to Multimodal Physical Therapy in Patients With Multiple Sclerosis
A randomized, parallel-group, clinical trial will be conducted to compare the immediate effects of the inclusion of a neurodynamic intervention into a multimodal physiotherapy program on pressure pain sensitivity, pain and manual dexterity in patients with multiple sclerosis
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
32
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Madrid
-
Alcorcon, Madrid, Spain, 28922
- César Fernández-de-las-Peñas
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- a diagnosis of multiple sclerosis according to the modified McDonald criteria;
- symptoms of paresthesia and lack of sensitivity in the upper extremity;
- Expanded Disability Status Scale (EDSS) between 0 and 6.5 points;
- absence of cognitive deficit.
Exclusion Criteria:
- any exacerbation of multiple sclerosis during the previous 3 months;
- previous hand surgery or steroid injections treatment in the upper extremity;
- multiple diagnoses on the upper extremity (e.g., cervical radiculopathy);
- cervical, shoulder, or upper extremity trauma;
- other comorbid musculoskeletal medical conditions;
- mini-mental state examination <25
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
ACTIVE_COMPARATOR: Physical Therapy
Patients will receive 5 session of multimodal physiotherapy treatment of 30min duration including low-load strength exercises, soft tissue mobilization and muscle-tendon stretching exercises twice per week.
|
Patients will receive 5 session of multimodal physiotherapy treatment of 30min duration including low-load strength exercises, soft tissue mobilization and muscle-tendon stretching exercises twice per week.
|
|
EXPERIMENTAL: Physical Therapy plus neurodynamic
Patients will receive 5 session of multimodal physiotherapy treatment of 30min duration including low-load strength exercises, soft tissue mobilization and muscle-tendon stretching exercises twice per week.
In addition, they will also receive bilateral nerve slider neurodynamic interventions targeting the median, ulnar and radial nerves.
|
Patients will receive 5 session of multimodal physiotherapy treatment of 30min duration including low-load strength exercises, soft tissue mobilization and muscle-tendon stretching exercises twice per week.
In addition, they will also receive bilateral nerve slider neurodynamic interventions targeting the median, ulnar and radial nerves.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes in pressure pain sensitivity
Time Frame: Baseline and one week after the last treatment session
|
Pressure pain threshold over the median, ulnar and radial nerves, second metacarpal and tibialis anterior
|
Baseline and one week after the last treatment session
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes in upper extremity pain intensity before and after the intervention
Time Frame: Baseline and one week after the last treatment session
|
A Numerical Pain Rate Scale (NPRS, 0-10) will be used to record the mean and the worst intensity of pain in te upper extremity
|
Baseline and one week after the last treatment session
|
|
Changes in light touch detection threshold
Time Frame: Baseline and after treatmentBaseline and one week after the last treatment session
|
Light touch detection threshold will be assessed with a standardized set of modified twenty von Frey hairs
|
Baseline and after treatmentBaseline and one week after the last treatment session
|
|
Changes in manual dexterity
Time Frame: Baseline and one week after the last treatment session
|
Bilateral manual dexterity was bilaterally assessed using the nine-hole peg test
|
Baseline and one week after the last treatment session
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
July 26, 2018
Primary Completion (ACTUAL)
September 15, 2018
Study Completion (ACTUAL)
October 4, 2018
Study Registration Dates
First Submitted
July 2, 2018
First Submitted That Met QC Criteria
July 12, 2018
First Posted (ACTUAL)
July 23, 2018
Study Record Updates
Last Update Posted (ACTUAL)
October 22, 2018
Last Update Submitted That Met QC Criteria
October 19, 2018
Last Verified
October 1, 2018
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PI-URJC 572
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.